Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ISPE Names Dr. Thomas Zimmer as Vice President of European Operations

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
Dr. Zimmer will be responsible for leading ISPE’s business development and advancing strategic relationships in Europe.

Dr. Zimmer began his work by engaging with global Members at ISPE’s Annual Meeting in Washington, DC. When he returns to Europe, Dr. Zimmer will work closely with ISPE’s volunteer and staff advisory teams, industry representatives, regulatory organizations and Member groups to strengthen ISPE’s relationships and deliver increasing value to ISPE’s European stakeholders. Dr. Zimmer will also serve as the primary European liaison to ISPE’s headquarters in Tampa, Fla. USA.

“Thomas joins ISPE with a strong foundation of pharmaceutical industry knowledge and relationships both within the Society and in the European professional community at large,” said ISPE President and CEO Nancy S. Berg. “Thomas’s first-hand knowledge of the European regulatory environment and industry processes will be an important asset to ISPE as it continues to build best-in-class knowledge transfer offerings that are tailored to the needs of the pharmaceutical and biopharmaceutical industries both in Europe and around the world.”

Dr. Zimmer joins ISPE with more than 30 years of experience in the pharmaceutical industry. He is a licensed pharmacist and Qualified Person. Prior to joining ISPE, Dr. Zimmer was Senior Vice President at Boehringer Ingelheim. During his 32 years with the company, he gained experience in development, production, quality and supply chain operations. Prior to becoming Senior Vice President, Dr. Zimmer served as Plant Manager in France, and he was International Project Leader for the Production Alliance Europe. He worked in various cultural environments in North America, South America and several countries in Europe. He holds a PhD in Pharmaceutical Technology from the University of Frankfurt am Main.

In addition to his professional experience, Dr. Zimmer has held numerous advisory posts within the pharmaceutical industry. He is a current member of the ISPE European Forum, a contributor to the ISPE Regulatory and Compliance Committee and a current member and former chair of the ISPE International Leadership Forum. Additionally, he is the former chair of the industrial advisory board of the University of Applied Sciences at the Beuth Institute in Berlin, former chair of the EFPIA Anti-counterfeiting working group, a former member of the WHO IMPACT taskforce, group regulatory enforcement, former chair of the board of directors for the PSI (Pharmaceutical Security Institute) and a former member in the EFPIA manufacturing GMP working group, product lifecycle team, technical development and operations committee TDOC. Dr. Zimmer has been an ISPE Member since 2005.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ISPE Announces Development of New Drug Shortages Prevention Plan
Drug Shortages Prevention Plan for the pharmaceutical and biopharmaceutical industry.
Tuesday, April 29, 2014
ISPE Issues Global Drug Shortage Survey
Preliminary results are expected in June 2013.
Tuesday, February 26, 2013
Risk-based Control Strategies in Pharmaceutical Industries at ISPE Brussels Conference
The conference will be the global launch of the Baseline® Guide: Risk-Based Manufacture of Pharmaceutical Products.
Friday, July 23, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!